Myo-inositol and an Antioxidant Mix for the Treatment of Vietnamese Infertile Men
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03726450 |
|
Recruitment Status : Unknown
Verified March 2019 by Hung Nguyen Ba, Andrology and Fertility Hospital of Hanoi.
Recruitment status was: Recruiting
First Posted : October 31, 2018
Last Update Posted : December 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Male Infertility | Dietary Supplement: Andrositol Plus | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 55 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Can Myo-inositol in Combination With N-Acetyl-Cysteine Plus an Antioxidant Mix be Useful for the Management of Men Affected by Idiopathic Infertility and Semen Hyperviscosity? |
| Actual Study Start Date : | November 1, 2018 |
| Estimated Primary Completion Date : | February 1, 2020 |
| Estimated Study Completion Date : | March 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Andrositol Plus
all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
|
Dietary Supplement: Andrositol Plus
Myo-inositol Dietary Supplement: Andrositol Plus N-Acetyl-Cysteine Dietary Supplement: Andrositol Plus Folic Acid Dietary Supplement: Andrositol Plus Selenium Dietary Supplement: Andrositol Plus L-arginine Dietary Supplement: Andrositol Plus L-carnitine Dietary Supplement: Andrositol Plus Vitamin E |
- change in sperm motility [ Time Frame: spermatozoa motility will be analyzed after 3 months of treatment ]spermatozoa motility will be evaluated through microscopical evalutation
- change in sperm morphology [ Time Frame: spermatozoa morphology will be analyzed at the enrollment and after 3 months of treatmentanalyzed ]spermatozoa morphology will be evaluated through microscopical evalutation
- change in sperm vitality [ Time Frame: spermatozoa vitality will be analyzed after 3 months of treatment ]spermatozoa vitality will be evaluated through vitality test with methylene blue
- change in sperm count [ Time Frame: spermatozoa count will be 3 months of treatment ]spermatozoa count will be evaluated through microscopical evalutation
- change in seminal fluid viscosity [ Time Frame: semen Hyper-viscosity will be analyzed after 3 months of treatment ]Viscosity will be determined after ejaculation by gently aspirating semen into a 5 ml pipette and then producing semen drops.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- BMI < 29
- One year of unsuccessful sexual intercourses without achieving pregnancy for male factor (idiopathic infertility)
- Normospermia, isolated asthenozoospermia and/or oligoasthenozoospermia
- Semen hyper-viscosity defined as severe, moderate and mild
Exclusion Criteria:
- The absence of spermatozoa production
- Positive presence of leucocyte and inflammation factor in the seminal fluid
- Positive urea test for the presence of bacteria, protozoa and/or fungi infection
- Diagnosis of cryptorchidism
- Diagnosis of Varicocele of grade 2 or higher
- Diagnosis of Diabetes and other pathology causing oxidative stress
- Concentration alterations of the following hormones: LH, FSH, Testosterone, Prolactin, 17b-estradiol
- Abuse of alcohol and controlled substance
- Smoking cigarettes (>10 cigarettes/day)
- BMI > 30
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03726450
| Vietnam | |
| Hung Nguyen | Recruiting |
| Hanoi, Vietnam | |
| Contact: Hung three Nguyen, Medical doctor +84 989 200 940 hung2779@gmail.com | |
| Responsible Party: | Hung Nguyen Ba, Andrologist, Andrology and Fertility Hospital of Hanoi |
| ClinicalTrials.gov Identifier: | NCT03726450 |
| Other Study ID Numbers: |
MAVIM |
| First Posted: | October 31, 2018 Key Record Dates |
| Last Update Posted: | December 12, 2019 |
| Last Verified: | March 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
myo-inositol N-acetyl-cysteine semen hyperviscosity idiopathic male infertility |
|
Infertility Infertility, Male |

